Amitiza's generic name is lubiprostone [1].
What is lubiprostone used for?
Lubiprostone is a medication used to treat chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation in adult women [1]. It works by increasing fluid secretion in the intestines, which helps to soften stool and stimulate bowel movements [1].
When did the patent for Amitiza expire?
The patent for Amitiza has faced challenges and expirations. For instance, a patent that was set to expire in 2027 was invalidated by a U.S. District Court in 2017 [2]. This means that generic versions of lubiprostone could become available earlier than anticipated.
Who manufactures generic lubiprostone?
Several pharmaceutical companies are involved in the production of generic lubiprostone. For example, Lupin Pharmaceuticals received approval from the U.S. Food and Drug Administration (FDA) for its generic lubiprostone capsules [3].
What are the potential side effects of lubiprostone?
Common side effects of lubiprostone include nausea, diarrhea, headache, and abdominal pain [1]. Patients experiencing severe diarrhea or dehydration should consult their doctor [1].
How does lubiprostone compare to other constipation treatments?
Lubiprostone is a prescription medication, differentiating it from over-the-counter options. Its mechanism of action, which increases intestinal fluid secretion, is distinct from bulk-forming laxatives or stimulant laxatives. Clinical data and physician guidance are important in determining the most appropriate treatment for individual constipation needs [1].
What is the regulatory status of generic lubiprostone?
Generic versions of lubiprostone must receive approval from regulatory bodies like the U.S. FDA before they can be marketed. This approval process ensures that generic drugs are bioequivalent to their brand-name counterparts and meet quality standards [3].
---
Sources
1. https://www.drugpatentwatch.com/drug/amitiza
2. https://www.drugpatentwatch.com/news/amitiza-patent-challenge- successo
3. https://www.drugpatentwatch.com/news/lupin-receives-fda-approval-for-generic-amitiza